Synonym
SR 47063; SR-47063; SR47063
IUPAC/Chemical Name
Cyanamide, (1-(2,2-dimethyl-6-nitro-2H-1-benzopyran-4-yl)-2(1H)-pyridinylidene)-
InChi Key
ZOHLDHMGABPLCB-KNTRCKAVSA-N
InChi Code
InChI=1S/C17H14N4O3/c1-17(2)10-14(20-8-4-3-5-16(20)19-11-18)13-9-12(21(22)23)6-7-15(13)24-17/h3-10H,1-2H3/b19-16+
SMILES Code
N#C/N=C1C=CC=CN\1C2=CC(C)(C)OC3=CC=C([N+]([O-])=O)C=C23
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
322.32
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Criddle DN, de Moura RS. Vasorelaxant effects of the potassium channel opener SR 47063 on the isolated human saphenous vein and rat aorta. Braz J Med Biol Res. 2000 Aug;33(8):961-6. doi: 10.1590/s0100-879x2000000800013. PMID: 10920439.
2: Forestier C, Pierrard J, Vivaudou M. Mechanism of action of K channel openers on skeletal muscle KATP channels. Interactions with nucleotides and protons. J Gen Physiol. 1996 Apr;107(4):489-502. doi: 10.1085/jgp.107.4.489. PMID: 8722562; PMCID: PMC2217007.
3: Forestier C, Depresle Y, Vivaudou M. Intracellular protons control the affinity of skeletal muscle ATP-sensitive K+ channels for potassium-channel- openers. FEBS Lett. 1993 Jul 5;325(3):276-80. doi: 10.1016/0014-5793(93)81088-h. PMID: 8391482.
4: Terrenoire C, Piriou V, Bonvallet R, Chouabe C, Espinosa L, Rougier O, Tourneur Y. Opposite effects of halothane on guinea-pig ventricular action potential duration. Eur J Pharmacol. 2000 Feb 25;390(1-2):95-101. doi: 10.1016/s0014-2999(00)00019-4. PMID: 10708711.
5: Dorman BH, Hebbar L, Zellner JL, New RB, Houck WV, Acsell J, Nettles C, Hendrick JW, Sampson AP, Mukherjee R, Spinale FG. ATP-sensitive potassium channel activation before cardioplegia. Effects on ventricular and myocyte function. Circulation. 1998 Nov 10;98(19 Suppl):II176-83. PMID: 9852901.
6: D'hahan N, Jacquet H, Moreau C, Catty P, Vivaudou M. A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K(+) channels by K(+) channel openers. Mol Pharmacol. 1999 Aug;56(2):308-15. doi: 10.1124/mol.56.2.308. PMID: 10419549.
7: Tourneur Y, Marion A, Gautier P. SR47063, a potent channel opener, activates KATP and a time-dependent current likely due to potassium accumulation. J Membr Biol. 1994 Dec;142(3):337-47. doi: 10.1007/BF00233440. PMID: 7707361.
